검색어: fluorokinoloni (슬로베니아어 - 영어)

fluorokinoloni (npr. moksifloksacin, sparfloksacin),
fluoroquinolones (e.g. moxifloxacin, sparfloxacin),

farmakoterapevtska skupina: fluorokinoloni, oznaka atc:
fluoroquinolones, atc code:

fluorokinoloni in nitrofurani učinkujejo medsebojno antagonistično.
antagonism may be observed with nitrofurantoin.

opazili so navzkrižno odpornost z drugimi fluorokinoloni.
cross-resistance is observed with other fluoroquinolones.

fluorokinoloni prehajajo skozi placento v materino mleko.
fluoroquinolones are known to cross the placenta and to be distributed into milk.

60/ 63 fluorokinoloni in nitrofurani učinkujejo medsebojno antagonistično.
61/ 64 overdose at very high doses adverse effects on the nervous system (ataxia, unsteadiness, twitching, tremors, convulsions, etc.) may occur in cattle; in this target species overdosing may also give rise to oedema and swelling in the knee joints.

opazili so navzkrižno odpornost med levofloksacinom in drugimi fluorokinoloni.
cross-resistance between levofloxacin and other fluoroquinolones is observed.

stopnja navzkrižne odpornosti med ciprofloksacinom in ostalimi fluorokinoloni je različna.
the degree of cross-resistance between ciprofloxacin and other fluoroquinolones that results is variable.

farmakoterapevtska skupina: kinolonske protimikrobne učinkovine, fluorokinoloni, oznaka atc:
quinolone antibacterials, fluoroquinolones, atc code:

fluorokinoloni in nitrofurani učinkujejo medsebojno antagonistično, posebno pri zdravljenju urinarnih infekcij.
nitrofurantoin may impair quinolone efficacy if used concurrently in the treatment of urinary tract infections.

Če je le mogoče, se zdravljenje s fluorokinoloni izvaja po predhodnem testiranju občutljivosti povzročiteljev.
whenever possible, fluoroquinolones should only be used based on susceptibility testing.

moksifloksacin, sparfloksacin (glejte poglavje 4.4 glede uporabe z drugimi fluorokinoloni)
moxifloxacin, sparfloxacin (see section 4.4 regarding use with other fluoroquinolones)

farmakoterapevtska skupina: zdravila za sistemsko zdravljenje bakterijskih infekcij, fluorokinoloni oznaka atc: j01ma12
pharmacotherapeutic group: antibacterials for systemic use, fluoroquinolones atc code: j01ma12

fluorokinoloni imajo protimikrobno učinkovanje tako proti mikroorganizmom, ne glede na to, ali so v fazi replikacije ali ne.
the fluoroquinolones exert their antibacterial effect against both replicating and dormant micro- organisms.

fluorokinoloni imajo protimikrobno učinkovanje tako proti mikroorganizmom, ki so v fazi replikacije, kot tistim, ki niso v tej fazi.
the fluoroquinolones exert their antibacterial effect against both replicating and non-replicating micro-organisms.

ne uporabite pri psih z motnjami centralnega živčnega sistema npr. epilepsijo, ker lahko fluorokinoloni povzročijo njen napad pri predisponiranih živalih.
do not use in dogs with central nervous system (cns) disorders, such as epilepsy, as fluoroquinolones could possibly cause seizures in predisposed animals.

ciprofloksacin in drugi fluorokinoloni lahko povzročijo fotosenzibilnost, zato naj se bolniki med zdravljenjem s ciprofloksacinom izogibajo dolgotrajni izpostavljenosti sončni svetlobi ali uv žarkom.
therefore, it is recommended to avoid prolonged exposure to sunlight or uv light during treatment with ciprofloxacin.

fluorokinoloni imajo protimikrobno učinkovanje tako proti mikroorganizmom, ki so v fazi replikacije, kot tistim, ki so v fazi transkripcije pri delitvi celic.
the fluoroquinolones exert their antibacterial effects against both replicating and dormant micro- organisms.

psi tako kot drugi fluorokinoloni tudi difloksacin učinkuje zaviralno na rast in obnavljanje sklepnega hrustanca, zato ga ne uporabite pri psih v fazi hitre rasti, ki je pri majhnih in srednje velikih pasmah
as for other quinolones, due to possible adverse effects on the articular cartilage of weight bearing joints difloxacin should not be used during the rapid growth phase, that is,. do not use in small and medium-sized breeds of dogs up to and including 8 months of age, in large breeds up to 1 year of age and in giant breeds up to 18 months of age.

odbor za zdravila za uporabo v humani medicini je navedel, da ciprofloksacin ni primeren za terapijo pnevmokokov ter da je njegova učinkovitost pri klamidiji slabša v primerjavi z drugimi fluorokinoloni, kot sta na primer levofloksacin ali moksifloksacin.
restriction of the indication “ infections of the lower respiratory tract” the chmp noted that ciprofloxacin was not suited for therapy of pneumococci and its efficacy against chlamydia was worse compared to other fluoroquinolones such as levofloxacin or moxifloxacin.